In Vitro & In Vivo Diagnostic Substances
Standard Industrial Classification: SIC 2835
Industry Insider Sentiment Analysis
The In Vitro & In Vivo Diagnostic Substances sector (SIC 2835) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-18 23:04 | 2024-06-14 | CLDX | Celldex Therapeutics, Inc. | Crowley Elizabeth | Officer | OPT+S | $34.87 | 30,000 | $1,045,962 | 9,074 |
| 2024-06-19 00:46 | 2024-06-14 | QDEL | QuidelOrtho Corp | Carlyle Group Inc. | 10% owner | SELL | $36.10 | 227,623 | $8,218,010 | 12,024,063 |
| 2024-06-18 23:12 | 2024-01-26 | AWH | Aspira Women's Health Inc. | SCHULER JACK W | 10% owner | BUY | $0.00 | 28,500 | $0 | 1,912,156 |
| 2024-06-17 23:30 | 2024-06-13 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Officer | SELL | $79.77 | 341 | $27,202 | 62,557 |
| 2024-06-15 00:02 | 2024-06-12 | QDEL | QuidelOrtho Corp | Carlyle Group Inc. | 10% owner | SELL | $38.46 | 208,497 | $8,018,461 | 12,251,686 |
| 2024-06-11 23:02 | 2024-06-07 | CLDX | Celldex Therapeutics, Inc. | Crowley Elizabeth | Officer | OPT+S | $35.06 | 15,000 | $525,873 | 9,074 |
| 2024-06-11 23:01 | 2024-06-07 | CLDX | Celldex Therapeutics, Inc. | Young Diane C. | Officer | SELL | $35.26 | 45,000 | $1,586,844 | 2,115 |
| 2024-06-05 23:04 | 2024-06-03 | CLDX | Celldex Therapeutics, Inc. | Jimenez Freddy A. | Officer | OPT+S | $33.60 | 8,006 | $269,002 | 25,924 |
| 2024-06-05 23:06 | 2024-06-03 | CLDX | Celldex Therapeutics, Inc. | Heath-Chiozzi Margo | Officer | OPT+S | $33.65 | 58,369 | $1,964,088 | 13,383 |
| 2024-06-05 23:05 | 2024-06-03 | CLDX | Celldex Therapeutics, Inc. | Wright Richard M. | Officer | OPT+S | $33.72 | 46,844 | $1,579,355 | 20,833 |
| 2024-06-04 23:30 | 2024-05-31 | LNTH | Lantheus Holdings, Inc. | Blanchfield Paul | Officer | SELL | $80.82 | 1,179 | $95,287 | 101,498 |
| 2024-06-05 00:57 | 2024-06-03 | MYGN | MYRIAD GENETICS INC | SPIEGELMAN DANIEL K | Director | SELL | $22.05 | 7,576 | $167,013 | 32,917 |
| 2024-06-04 00:30 | 2024-05-31 | AWH | Aspira Women's Health Inc. | Sandford Nicole | Director, Officer | BUY | $2.42 | 9,493 | $22,973 | 70,596 |
| 2024-06-03 23:06 | 2024-05-30 | CLDX | Celldex Therapeutics, Inc. | Heath-Chiozzi Margo | Officer | OPT+S | $34.07 | 38,719 | $1,319,156 | 7,094 |
| 2024-06-03 23:04 | 2024-05-30 | CLDX | Celldex Therapeutics, Inc. | Cavanaugh Sarah | Officer | OPT+S | $33.73 | 20,853 | $703,334 | 1,860 |
| 2024-06-03 23:05 | 2024-05-30 | CLDX | Celldex Therapeutics, Inc. | Martin Samuel Bates | Officer | OPT+S | $34.05 | 35,000 | $1,191,775 | 25,128 |
| 2024-06-03 23:04 | 2024-05-30 | CLDX | Celldex Therapeutics, Inc. | Crowley Elizabeth | Officer | OPT+S | $33.64 | 38,597 | $1,298,384 | 9,074 |
| 2024-06-03 23:30 | 2024-05-30 | LNTH | Lantheus Holdings, Inc. | Niedzwiecki Daniel | Officer | SELL | $79.86 | 12,873 | $1,028,038 | 80,244 |
| 2024-05-30 23:34 | 2024-05-28 | LNTH | Lantheus Holdings, Inc. | Maeusli Heinz Christoph | Director | OPT+S | $79.19 | 18,373 | $1,454,989 | 23,340 |
| 2024-05-30 23:32 | 2024-05-28 | LNTH | Lantheus Holdings, Inc. | McHugh Julie | Director | SELL | $78.50 | 2,500 | $196,250 | 28,617 |
| 2024-05-21 00:00 | 2024-05-17 | IDXX | IDEXX LABORATORIES INC /DE | Claflin Bruce L. | Director | SELL | $540.80 | 200 | $108,160 | 161 |
| 2024-05-16 00:48 | 2024-05-13 | MYGN | MYRIAD GENETICS INC | Newcomer Lee Nisley | Director | SELL | $25.30 | 6,200 | $156,860 | 66,650 |
| 2024-05-16 00:09 | 2024-05-13 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Officer | SELL | $76.89 | 341 | $26,219 | 62,898 |
| 2024-05-16 00:49 | 2024-05-13 | MYGN | MYRIAD GENETICS INC | DIAZ PAUL J | Director, Officer | SELL | $25.14 | 227,844 | $5,728,773 | 1,066,166 |
| 2024-04-17 19:04 | 2024-04-17 | NEOG | NEOGEN CORP | Jones Douglas Edward | Officer | BUY | $12.36 | 10,000 | $123,590 | 46,131 |
| 2024-04-17 23:30 | 2024-04-15 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Officer | SELL | $61.24 | 341 | $20,883 | 63,239 |
| 2024-04-15 13:04 | 2024-04-11 | OCX | Insight Molecular Diagnostics Inc. | Riggs Josh | Director, Officer | BUY | $2.95 | 3,390 | $10,001 | 3,505 |
| 2024-04-15 13:02 | 2024-04-11 | OCX | Insight Molecular Diagnostics Inc. | Arno Andrew | Director | BUY | $2.95 | 33,898 | $99,999 | 69,054 |
| 2024-04-16 02:21 | 2024-04-11 | OCX | Insight Molecular Diagnostics Inc. | BROADWOOD PARTNERS, L.P. | 10% owner | BUY | $2.92 | 2,420,000 | $7,057,688 | 4,929,066 |
| 2024-04-11 18:40 | 2024-04-11 | NEOG | NEOGEN CORP | BOREL JAMES C | Director | BUY | $13.06 | 7,500 | $97,986 | 21,392 |
| 2024-04-10 23:18 | 2024-04-10 | NEOG | NEOGEN CORP | Naemura David H. | Officer | BUY | $12.51 | 12,500 | $156,321 | 30,040 |
| 2024-04-10 21:25 | 2024-04-10 | NEOG | NEOGEN CORP | ADENT JOHN EDWARD | Officer | BUY | $12.36 | 23,000 | $284,190 | 152,389 |
| 2024-03-19 23:30 | 2024-03-15 | LNTH | Lantheus Holdings, Inc. | Marshall Robert J. Jr. | Officer | SELL | $60.00 | 20,000 | $1,200,000 | 113,749 |
| 2024-03-15 23:30 | 2024-03-13 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Officer | SELL | $60.48 | 341 | $20,624 | 63,204 |
| 2024-03-11 23:30 | 2024-03-07 | LNTH | Lantheus Holdings, Inc. | Blanchfield Paul | Officer | SELL | $61.96 | 18,023 | $1,116,705 | 103,357 |
| 2024-03-08 01:00 | 2024-03-05 | IDXX | IDEXX LABORATORIES INC /DE | Vandebroek Sophie V. | Director | OPT+S | $562.98 | 1,404 | $790,427 | 1,216 |
| 2024-03-08 01:00 | 2024-03-06 | IDXX | IDEXX LABORATORIES INC /DE | POLEWACZYK JAMES F | Officer | OPT+S | $558.44 | 8,104 | $4,525,596 | 10,711 |
| 2024-03-08 00:30 | 2024-03-05 | LNTH | Lantheus Holdings, Inc. | LENO SAM R | Director | OPT+S | $64.06 | 4,090 | $262,005 | 57,937 |
| 2024-03-07 00:49 | 2024-03-04 | ACHV | ACHIEVE LIFE SCIENCES, INC. | Stewart Richard Alistair | Director, Officer | BUY | $4.59 | 10,000 | $45,850 | 38,501 |
| 2024-03-07 00:43 | 2024-03-04 | ACHV | ACHIEVE LIFE SCIENCES, INC. | Bencich John | Director, Officer | BUY | $4.59 | 10,000 | $45,850 | 76,724 |
| 2024-03-07 01:15 | 2024-03-04 | LNTH | Lantheus Holdings, Inc. | LENO SAM R | Director | OPT+S | $65.42 | 22,389 | $1,464,749 | 57,937 |
| 2024-03-06 00:10 | 2024-03-04 | NTLA | Intellia Therapeutics, Inc. | BASTA JAMES | Officer | SELL | $32.99 | 2,297 | $75,778 | 81,571 |
| 2024-03-06 00:10 | 2024-03-04 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | Officer | SELL | $32.99 | 605 | $19,959 | 71,470 |
| 2024-03-06 04:28 | 2024-03-04 | LNTH | Lantheus Holdings, Inc. | Heino Mary Anne | Director | SELL | $65.31 | 93,863 | $6,129,892 | 251,643 |
| 2024-02-28 00:21 | 2022-08-15 | TKNO | Alpha Teknova, Inc. | Grossman Paul David | Director | BUY | $5.37 | 9,212 | $49,504 | 9,212 |
| 2024-02-27 02:48 | 2024-02-23 | QDEL | QuidelOrtho Corp | Busky Joseph M | Officer | BUY | $46.36 | 2,150 | $99,663 | 2,150 |
| 2024-02-16 00:30 | 2024-02-13 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Officer | SELL | $55.31 | 341 | $18,861 | 58,403 |
| 2024-02-10 01:00 | 2024-02-07 | IDXX | IDEXX LABORATORIES INC /DE | MAZELSKY JONATHAN JAY | Director, Officer | OPT+S | $572.61 | 12,000 | $6,871,319 | 79,247 |
| 2024-02-10 01:03 | 2024-02-08 | IDXX | IDEXX LABORATORIES INC /DE | FENNELL GEORGE | Officer | OPT+S | $573.87 | 8,198 | $4,704,558 | 6,712 |
| 2024-02-10 01:01 | 2024-02-07 | IDXX | IDEXX LABORATORIES INC /DE | MCKEON BRIAN P | Officer | OPT+S | $570.01 | 23,326 | $13,295,974 | 29,718 |
Sector-Wide Insider Alpha
Analyzing insider movements across the In Vitro & In Vivo Diagnostic Substances sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2835) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in In Vitro & In Vivo Diagnostic Substances
Every transaction in the In Vitro & In Vivo Diagnostic Substances industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.